Compare CASH & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CASH | OGN |
|---|---|---|
| Founded | 1954 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 1996 | 2020 |
| Metric | CASH | OGN |
|---|---|---|
| Price | $82.52 | $13.39 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | ★ $107.50 | $11.40 |
| AVG Volume (30 Days) | 181.3K | ★ 2.6M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | 0.23% | ★ 0.60% |
| EPS Growth | ★ 18.88 | N/A |
| EPS | ★ 4.89 | 0.55 |
| Revenue | $839,894,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $7.56 | $0.45 |
| Revenue Next Year | $6.02 | $1.67 |
| P/E Ratio | ★ $16.78 | $24.42 |
| Revenue Growth | ★ 11.29 | N/A |
| 52 Week Low | $65.93 | $5.69 |
| 52 Week High | $101.26 | $13.49 |
| Indicator | CASH | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 49.91 | 68.61 |
| Support Level | $81.14 | $10.05 |
| Resistance Level | $84.62 | $13.46 |
| Average True Range (ATR) | 2.28 | 0.05 |
| MACD | 0.44 | -0.11 |
| Stochastic Oscillator | 59.40 | 23.08 |
Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.